<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336496">
  <stage>Registered</stage>
  <submitdate>4/02/2011</submitdate>
  <approvaldate>18/02/2011</approvaldate>
  <actrnumber>ACTRN12611000193976</actrnumber>
  <trial_identification>
    <studytitle>Impact of the Three Gorges Dam on transmission and future control of human schistosomiasis in China</studytitle>
    <scientifictitle>Multi-factorial randomised trial of integrated control on schistosomiasis incidence</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schistosomiasis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Annual human praziquantel (single dose 40mg/kg oral tablet)

Annual bovine praziquantel (single dose 25mg/kg oral tablet), 

Molluscicide: Niclosamide (2 g/m2) spray annually, 

Bovine vaccine SjCTPI-Hsp70/IL-12 DNA vaccine (single dose 500ug IM injection) (1 primary + 1 boost year 1; annual boost years 2-4)



Intervention	Vaccinated Bovines	Placebo Bovines

Mollusciciding	2 villages 	                2 villages 
Human PZQ	2 villages  	2 villages 
Neither	                2 villages	                2 villages (Control)</interventions>
    <comparator>Bovine: Placebo (pVAX plasmid DNA) (single dose 500ug IM injection) (1 primary + 1 boost year 1; annual boost years 2-4),

Human: Standard Treatment (single dose praziquantel 40mg/kg oral tablet)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Human schistosomiasis incidence</outcome>
      <timepoint>2010 (Year 1), 2012, 2014 (end of trial)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Bovine schistosomiasis incidence</outcome>
      <timepoint>2010 (Year 1), 2012, 2014 (end of trial)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Density of infected snails

To determine the density of infected oncomelanids per unit area, snails will be collected from randomly placed 4m2 frames within a 10000 square meter area adjoining each of the study villages.  Snails will then be examined microscopically for the presence of schistosome larvae</outcome>
      <timepoint>2010 (Year 1), 2012, 2014 (end of trial)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Resident of the administrative village and/or natural village selected for study.

2. Has been a resident of the village for &gt;12 months.

3. 5-65 years of age.

4. Will not be migrating in the next 4 years.

5. Those who continuously reside in the study area over the study period.

6. The resident has given informed consent.

7. Minors have the informed consent of their parent/guardian.</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. No consent

2. Resides less than 6 months of the year in the village</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/12/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>6000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hunan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Queensland Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress>Queensland Institute of Medical Research 
300 Herston Road, Brisbane, Queensland 4006, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (Australia)</fundingname>
      <fundingaddress>Telephone 13 000 NHMRC (13 000 64672) 
or +61 2 6217 9000 
Fax +61 2 6217 9100 
Email nhmrc@nhmrc.gov.au  
Street Level 1
16 Marcus Clarke Street
Canberra ACT 2601  
Postal National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Donald P McManus</sponsorname>
      <sponsoraddress>Queensland Institute of Medical Research 
300 Herston Road, Brisbane, Queensland 4006, Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Hunan Institute of Parasitic Diseases</othercollaboratorname>
      <othercollaboratoraddress>Hunan Institute of Parasitic Diseases, WHO Collaborating Centre for Research and Control of Schistosomiasis on Lake Region
No 258 Jine Middle Road
Yueyang, Hunan province, 414000, The Peoples Republic of China
Tel: 86 730 8515009, Fax 86 730 8623018</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Our central thesis is that: When the TGD becomes fully operational in 2009, a wide variety of environmental and ecological changes will result downstream, impacting directly on the density and reproduction of the oncomelanid snail hosts for Schistosoma japonicum. The period that follows is critical as this will be the only time that the immediate effects of the TGD on schistosome transmission can be determined. It is predicted that The Dam will influence the transmission dynamics of human schistosomiasis, resulting in a substantially increased disease burden in communities along the Yangtze River, which will require an integrated control strategy to reduce the rate of transmission of S. japonicum from bovines and humans to snails.

With this background, we will test the following specific hypotheses:

1.  When fully operational in 2009, the TGD will result in reduced flooding in the downstream endemic areas extending the transmission season and  expanding  marshland areas, which will provide opportunities for the reproduction, dispersal and increased density of infected Oncomelania snails and hyper-endemic S. japonicum transmission.

2.  The changing transmission dynamics will require improved cost-effective methods of surveillance and integrated schistosomiasis control. 	

We will quantify the impact of integrated strategies for schistosomiasis control using a multi-factorial randomised design. The strategies we will employ are: 

1.Combined human mass chemotherapy and bovine vaccination; 

2.Combined bovine vaccination with mollusciciding of snails.</summary>
    <trialwebsite>N/A</trialwebsite>
    <publication>Gray, D.J., McManus, D.P., Li, Y.S., Williams, G.M., Bergquist, R., Ross, A.G. (2010) Schistosomiasis elimination: Lessons from the past guide the future. Lancet Infectious Diseases 10: 733-736.

McManus, D.P., Gray, D.J., Li, Y.S., Feng, Z., Williams, G.M., Stewart, D., Rey-Ladino, J., Ross, A.G. (2010) Schistosomiasis in the Peoples Republic of China: The era of the Three Gorges Dam. Clinical Microbiology Reviews 23: 442-466

Gray, D.J., Williams, G.M., Li, Y.S., Chen, H.G., Forsyth, S.J., Li, R.S., Barnett, A.G., Guo, J.G., Ross, A.G., Feng, Z., McManus, D.P. (2009) A cluster-randomised intervention trial against S. japonicum in the Peoples' Republic of China: Bovine and human transmission. PLoS ONE 4(6): e5900</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland Institute of Medical Research HREC</ethicname>
      <ethicaddress>Queensland Institute of Medical Research
300 Herston Road, Brisbane, Queensland 4006, Australia</ethicaddress>
      <ethicapprovaldate />
      <hrec>H0309-058 (P524)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Donald P McManus</name>
      <address>Queensland Institute of Medical Research 
300 Herston Road, Brisbane, Queensland 4006, Australia</address>
      <phone>+617 33620401</phone>
      <fax />
      <email>Donald.McManus@qimr.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Donald P McManus</name>
      <address>Queensland Institute of Medical Research 
300 Herston Road, Brisbane, Queensland 4006, Australia</address>
      <phone>+617 33620401</phone>
      <fax>+617 33620104</fax>
      <email>Donald.McManus@qimr.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Darren J Gray</name>
      <address>Queensland Institute of Medical Research 
300 Herston Road, Brisbane, Queensland 4006, Australia</address>
      <phone />
      <fax />
      <email>Darren.Gray@qimr.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>